Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Pracinostat |
Synonyms | |
Therapy Description |
Pracinostat (SB939) is a histone deacetylase (HDAC) inhibitor, with limited activity against HDAC6, which may reduce tumor cell proliferation and tumor growth (PMID: 20197387, PMID: 32109485). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Pracinostat | SB939|SB-939 | HDAC Inhibitor 45 | Pracinostat (SB939) is a histone deacetylase (HDAC) inhibitor, with limited activity against HDAC6, which may reduce tumor cell proliferation and tumor growth (PMID: 20197387, PMID: 32109485). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01993641 | Phase II | Pracinostat Azacitidine Decitabine | Phase 2 Study Adding Pracinostat to a Hypomethylating Agent (HMA) in Patients With MDS Who Failed to Respond to Single Agent HMA | Completed | USA | 0 |